Intelligence · Clinical pipeline
Infectious disease · Phase II
Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Infectious disease Phase II programs: NovaPharmaNews indexes 365 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 27 programs
- United Therapeutics Europe 23 programs
- Chinese Academy of 16 programs
- Takeda 16 programs
- Vir Biotechnology 15 programs
- Vertex Pharmaceuticals (Australia) 12 programs
- Sinovac Research and 11 programs
- GSK Glaxo Smith 10 programs
- ENANTA PHARMACEUTICALS 8 programs
- Arrowhead Pharmaceuticals Ireland 7 programs
- Regeneron UK 7 programs
- Anaxis Pharma 6 programs
Pipeline programs
-
Vaccine PvCS N+C+R 150 mcg
BRIGHT MINDS BIOSCIENCES INC.
Malaria, Vivax
1 trial -
Vancomycin
Cardiff Oncology
Late Onset Neonatal Sepsis
1 trial -
Veklury 100 mg powder for concentrate for solution for infusion
MEDA Pharma GmbH & Co. KG
COVID-10 infection
1 trial -
Visual match to product
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
Voclosporin
Aurinia Pharmaceuticals
Covid19
1 trial -
Vortioxetine
COGNITION THERAPEUTICS INC
Post-COVID-19 Condition
1 trial -
Workshop
BRIGHT MINDS BIOSCIENCES INC.
HIV
1 trial -
accelerated intermittent theta burst stimulation
United Therapeutics Europe Ltd
Long COVID
1 trial -
alb-interferon alfa 2b
Novartis Pharmaceuticals
Chronic Hepatitis C
1 trial -
casirivimab+imdevimab
Regeneron UK Limited
COVID-19
2 trials -
coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
BRIGHT MINDS BIOSCIENCES INC.
HIV
1 trial -
dronabinol
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial -
empowerment theory-based small group discussion
BRIGHT MINDS BIOSCIENCES INC.
HIV Infection
1 trial -
lanadelumab
Takeda
COVID-19
1 trial -
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
meningococcal ACWY (vaccine)
GlaxoSmithKline
Infections, Meningococcal
1 trial -
middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Norovirus Infections
1 trial -
oritavancin
Targanta Netherlands B.V.
Staphylococcal Skin Infections
1 trial -
placebo
The First People's Hospital of Lianyungang
COVID-19 Thalidomide
1 trial -
pneumococcal polysaccharide and protein conjugate vaccines
United Therapeutics Europe Ltd
Pneumococcal Infections
1 trial -
ribavirin (RBV)
Boehringer Ingelheim
Hepatitis C
1 trial -
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
standard triple region
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Helicobacter Pylori Infection
1 trial -
sterile saline solution (0.9% w/v solution of NaCl in water).
GlaxoSmithKline
Urinary Tract Infections
1 trial -
telaprevir
Vertex Pharmaceuticals (Australia) Pty.
Chronic Hepatitis C Virus Infection
1 trial -
telaprevir or matching placebo
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C
1 trial -
thalidomide
Ultragenyx UK Limited
HIV Infections
1 trial -
zelicapavir
ENANTA PHARMACEUTICALS INC
RSV Infection
1 trial -
zinc supplementation
United Therapeutics Europe Ltd
HIV Infections
1 trial
Frequently asked questions
How many infectious disease Phase II programs exist?
365 programs match both the therapeutic area and stage filters in our published index.